Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections

Laith J. Abu-Raddad, Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, Peter Coyle, Mohammad R. Hasan, Hadi M. Yassine, Fatiha M. Benslimane, Hebah A. Al Khatib, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al Kuwari, Adeel A. Butt, Hamad Eid Al Romaihi, Abdullatif Al Khal, Mohamed H. Al-Thani, Roberto Bertollini
doi: https://doi.org/10.1101/2021.07.28.21261086

Abstract

SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. The RT-qPCR cycle threshold (Ct) value is inversely correlated with viral load and culturable virus. Here, we investigated differences in RT-qPCR Ct values across Qatar’s national cohorts of primary infections, reinfections, BNT162b2 (Pfizer-BioNTech) breakthrough infections, and mRNA-1273 (Moderna) breakthrough infections. Through matched-cohort analyses of the randomly diagnosed infections, the mean Ct value was higher in all cohorts of breakthrough infections compared to the cohort of primary infections in unvaccinated individuals. The Ct value was 1.3 (95% CI: 0.9-1.8) cycles higher for BNT162b2 breakthrough infections, 3.2 (95% CI: 1.8-4.5) cycles higher for mRNA-1273 breakthrough infections, and 4.0 (95% CI: 3.4-4.6) cycles higher for reinfections in unvaccinated individuals. Assuming a linear relationship between viral load and infectiousness, these differences imply that breakthrough infections are at least 50% less infectious than primary infections in unvaccinated individuals. Public health benefits of vaccination may have been underestimated, as COVID-19 vaccines not only protect against acquisition of infection, but also appear to protect against transmission of infection.

Introduction

Coronavirus Disease 2019 (COVID-19) vaccines have demonstrated protection against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1–3. However, the efficacy against acquisition of infection is imperfect in that vaccines have an efficacy VES < 100%, particularly against variants of concern4,5. Breakthrough infections in vaccinated individuals have been documented in various countries4–6, but the transmission potential of these infections is poorly understood. It is conceivable that vaccinated persons who acquire the infection may be less infectious than unvaccinated persons who acquire the infection, as the vaccine-primed immune response may attenuate the natural history of infection and reduce viral replication, leading to lower viral load and faster infection clearance7. There is evidence that seem to support this hypothesis for SARS-CoV-2 infection8,9. Therefore, COVID-19 vaccines may not only be efficacious against acquisition of infection (VES), but also against transmission of infection7, thereby adding additional efficacy for each vaccine, denoted as VEI and defined as the proportional reduction in infectiousness among those infected, but vaccinated, compared to those infected but unvaccinated7.

Leveraging the national, federated databases that have captured all SARS-CoV-2 vaccinations and polymerase chain reaction (PCR) testing in Qatar since the start of the epidemic (Methods), we investigated the effect of vaccination on infectiousness by comparing SARS-CoV-2 real time (quantitative) reverse transcription-PCR (RT-qPCR) cycle threshold (Ct) values of individuals infected and fully vaccinated with the values of those infected and unvaccinated. The RT-qPCR Ct value is a measure of the inverse of viral load and correlates strongly with culturable virus10; thus, it can be used as a proxy of SARS-CoV-2 infectiousness10. We also investigated the effect of prior infection on infectiousness at reinfection by comparing the RT-qPCR Ct values among those reinfected with SARS-CoV-2 with the values among those in primary infection.

These comparisons were implemented utilizing: i) the national cohort of all 384,452 RT-qPCR-confirmed primary infections since epidemic onset (February 28, 2020) until the end of the study (July 11, 2021; Figure 1A); ii) the national cohort of all 1,695 RT-qPCR-confirmed reinfections during the same period (Figure 1B); iii) the national cohort of all 898,648 individuals vaccinated with the BNT162b21 (Pfizer-BioNTech) vaccine since the first recorded vaccination in Qatar on December 16, 2020 until the end of the study (July 11, 2021; Figure 1C); and iv) the national cohort of all 468,872 vaccinated individuals with the mRNA-12732 (Moderna) vaccine during the same period (Figure 1D).

Figure 1.
Figure 1.

Flowchart illustrating the selection of the cohorts of primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections.

The BNT162b2 and mRNA-1273 vaccines have been the vaccines of choice in the national immunization campaign in Qatar4,5,11,12. In total, there has been 4,777 breakthrough infections in those fully vaccinated with BNT162b2 (0.61% of those fully vaccinated; Figure 1C) and 306 mRNA-1273 breakthrough infections in those fully vaccinated with mRNA-1273 (0.09% of those fully vaccinated; Figure 1D). Of note that mass immunization started with the BNT162b2 vaccine, and the mRNA-1273 vaccine was introduced only several weeks later.

Primary infection was defined as the first RT-qPCR-positive test for a given individual. Reinfection was defined as the first RT-qPCR-positive test that occurred ≥90 days after the primary infection13–16. Breakthrough infection in a vaccinated individual was defined as an RT-qPCR-positive test 14 or more days after the individual received the second vaccine dose, conditional on this RT-qPCR-positive test being the first ever positive for this individual.

Results

Study populations

Figure 1 shows the process for identifying eligible primary infections, reinfections, BNT162b2 breakthrough infections, and mRNA-1273 breakthrough infections. Figure 2 schematizes the six pairwise comparisons conducted between these cohorts of infections, after matching in a 1:1 ratio by sex, 10-year age group, reason for RT-qPCR testing, and calendar week of the RT-qPCR test, to control for differences in biology by sex and age, as well as exposure risk17,18 and variant exposure4,19,20 (Methods).

Figure 2.
Figure 2.

Schematic diagram showing the process of formulating the six pairwise comparisons between the cohorts of primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections, after 1:1 matching by sex, 10-year age group, reason for RT-qPCR testing, and calendar week of the RT-qPCR test.

Supplementary Tables 1 and 2 show demographic characteristics of the study populations in the six pairwise comparisons. Scatter plots of the distribution of RT-qPCR Ct values in each comparison were generated for all RT-qPCR-confirmed infections, regardless of the reason for the RT-qPCR testing (Supplementary Figure 1), only for the randomly diagnosed (asymptomatic) infections (Figure 3; Methods), and only for the symptomatic infections (Supplementary Figure 2; Methods).

Figure 3.
Figure 3.

RT-qPCR Ct values in the randomly diagnosed (asymptomatic) SARS-CoV-2 infections. Distribution of these Ct values in the six pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections. A randomly diagnosed infection was defined as an RT-qPCR-positive test conducted with no prior reason to suspect infection and no reported presence of symptoms compatible with a respiratory tract infection. That is, the RT-qPCR test was conducted as part of a survey (random testing campaigns), for routine healthcare testing, for pre-travel requirement, or at port of entry upon arrival in Qatar. Boxplots center lines indicate the median Ct values, box limits indicate the 25% and 75% quartiles, and whiskers indicate maximum and minimum observations within 1.5 of interquartile range.

Differences in RT-qPCR Ct values in all confirmed infections

In the comparisons including all RT-qPCR-confirmed infections, regardless of the reason for the RT-qPCR testing, the mean RT-qPCR Ct value was higher in all cohorts of breakthrough infections compared to the cohort of primary infections in unvaccinated individuals (Table 1 and Supplementary Figure 1). The Ct value was 1.0 (95% confidence interval (CI): 0.7-1.2) cycles higher for BNT162b2 breakthrough infections, 3.5 (95% CI: 2.4-4.6) cycles higher for mRNA-1273 breakthrough infections, and 3.7 (95% CI: 3.4-4.2) cycles higher for reinfections in unvaccinated individuals. The Ct value was 3.1 (95% CI: 1.9-4.3) cycles higher in mRNA-1273 breakthrough infections than in BNT162b2 breakthrough infections. Compared to reinfections in unvaccinated individuals, the Ct value was 2.0 (95% CI: 0.2-3.9) cycles lower in mRNA-1273 breakthrough infections and 1.7 (95% CI: 1.1-2.4) cycles lower in BNT162b2 breakthrough infections. All differences in Ct values were statistically significant with p-values ≤0.03.

View this table:
Table 1.

RT-qPCR Ct values, including all confirmed infections, regardless of the reason for the RT-qPCR testing, in the six pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections.

Differences in RT-qPCR Ct values in randomly diagnosed infections

In the comparisons including only the randomly diagnosed (asymptomatic) infections (Methods), which are perhaps most representative for differences between these cohorts of infections, given the random diagnosis, the mean RT-qPCR Ct value was also higher in all cohorts of breakthrough infections compared to the cohort of primary infections in unvaccinated individuals (Table 2 and Figure 3). The Ct value was 1.3 (95% CI: 0.9-1.8) cycles higher for BNT162b2 breakthrough infections, 3.2 (95% CI: 1.8-4.5) cycles higher for mRNA-1273 breakthrough infections, and 4.0 (95% CI: 3.4-4.6) cycles higher for reinfections in unvaccinated individuals. The Ct value was 2.3 (95% CI: 0.8-3.7) cycles higher in mRNA-1273 breakthrough infections than in BNT162b2 breakthrough infections. Compared to reinfections in unvaccinated individuals, the Ct value was 2.0 (95% CI: 1.1-2.8) cycles lower in BNT162b2 breakthrough infections and 1.7 (95% CI: (−0.4-3.8) cycles lower in mRNA-1273 breakthrough infections. All differences in Ct values were statistically significant with p-values ≤0.003 except for the comparison between reinfections and mRNA-1273 breakthrough infections; likely a consequence of the small number of breakthrough infections that have been documented among those vaccinated with the mRNA-1273 vaccine in Qatar.

View this table:
Table 2.

RT-qPCR Ct values, including only the randomly diagnosed (asymptomatic) infections, in the six pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections. A randomly diagnosed infection is defined as an RT-qPCR-positive test conducted with no prior reason to suspect infection and no reported presence of symptoms compatible with a respiratory tract infection.

Differences in RT-qPCR Ct values in symptomatic infections

In the comparisons including only the symptomatic infections (Methods), the mean RT-qPCR Ct value was also higher in all cohorts of breakthrough infections compared to the cohort of primary infections in unvaccinated individuals, but the difference was smaller for BNT162b2 breakthrough infections (Table 3 and Supplementary Figure 2). The Ct value was 0.2 (95% CI: - 0.2-0.6) cycles higher for BNT162b2 breakthrough infections, 4.9 (95% CI: 2.4-7.4) cycles higher for mRNA-1273 breakthrough infections, and 3.8 (95% CI: 2.8-4.7) cycles higher for reinfections in unvaccinated individuals. The Ct value was 5.3 (95% CI: 2.5-8.2) cycles higher in mRNA-1273 breakthrough infections than in BNT162b2 breakthrough infections. Compared to reinfections in unvaccinated individuals, the Ct value was 1.8 (95% CI: 0.6-3.1) cycles lower in BNT162b2 breakthrough infections and 6.4 (95% CI: 1.3-11.6) cycles lower in mRNA-1273 breakthrough infections. All differences in Ct values were statistically significant with p-values ≤0.016 except for the comparison between primary infections and BNT162b2 breakthrough infections. Notably, very few symptomatic mRNA-1273 breakthrough infections have been documented in Qatar (Table 3).

View this table:
Table 3.

RT-qPCR Ct values, including only the symptomatic infections, in the six pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections.

Differences in SARS-CoV-2 viral load and infectiousness

These differences in Ct values can be translated into approximate relative differences in viral load (Methods). Since the mathematical formula linking viral load to Ct value has an exponential form (viral load is proportional to 2−n where n is the RT-qPCR Ct value)21, small differences in Ct value represent large differences in viral load.

Empirically, SARS-CoV-2 viral load strongly correlates with culturable virus10, just as viral load for other viruses, such as HIV, is a measure of its infectiousness22–24. Therefore, relative differences in viral load can be considered as a proxy measure of relative differences in infectiousness (Methods), that is VEI 7. For instance, assuming that SARS-CoV-2 infectiousness is linearly proportional to viral load, the simplest default assumption, a Ct value higher by 1.0 cycle corresponds to a lower viral load (and infectiousness) by a factor of 2 (2−1.0 = 1/2), that is a VEI = 50%.

Table 5 shows approximate estimates for the relative infectiousness of SARS-CoV-2 infections across the cohorts of primary infections, reinfections, BNT162b2 breakthrough infections, and mRNA-1273 breakthrough infections, assuming that SARS-CoV-2 infectiousness is linearly proportional to viral load. Meanwhile, Table 6 shows the same estimates in a sensitivity analysis assuming that infectiousness is (non-linearly) proportional to some power of viral load (vlα), just as for HIV infection which has perhaps the best characterized relationship between viral load and infectiousness in the literature22–24. Here, the exponent α has been estimated at around 0.422- 24—that is infectiousness is approximately proportional to the square rate of viral load rather than the viral load itself.

In both sets of estimates, breakthrough infections in those vaccinated or who had a prior infection had substantially lower infectiousness than primary infections in unvaccinated persons. For example, in the randomly diagnosed infections and assuming that infectiousness is linearly proportional to viral load, BNT162b2 breakthrough infections, mRNA-1273 breakthrough infections, and reinfections were only 0.41-fold (95% CI: 0.29-0.54), 0.11-fold (95% CI: 0.04-0.29), and 0.06-fold (95% CI: 0.04-0.09) as infectious as primary infections, respectively. The different comparisons suggest an overall hierarchy, present for both asymptomatic and symptomatic infections, where primary infections in unvaccinated persons are most infectious, followed by BNT162b2 breakthrough infections, mRNA-1273 breakthrough infections, and finally reinfections in unvaccinated persons.

Discussion

Breakthrough infections in those vaccinated or who had a prior infection have higher RT-qPCR Ct values than primary infections in unvaccinated persons. While these breakthrough infections are not uncommon, the results indicate that they have lower viral load and are less likely to be infectious than primary infections. While some of these breakthrough infections could lead to secondary transmissions, and indeed some of them did have high viral loads (Figure 3 and Supplementary Figure 1 and 2), the risk of onward transmission appears to be substantially reduced, compared to primary infections. Thus, they are of less public health concern.

A consequence of these findings is that the public health benefits of vaccination may be underestimated. In addition to the conventional vaccine efficacy against acquisition of infection (VES) that is assessed in randomized clinical trials1–3, there is an additional “breakthrough” efficacy against transmission (VEI) that augments the benefits of VES (Tables 5 and 6), at least for the BNT162b2 and mRNA-1273 vaccines investigated in this study. The existence of this additional VEI efficacy implies that the reproduction number (R0) after vaccination is lower than current estimates7. SARS-CoV-2 incidence may decline faster with vaccine scale up7, and herd immunity may be easier to achieve, at somewhat lower vaccine coverage than previously predicted7.

One finding of this study is that there appears to be a hierarchy in infectiousness of SARS-CoV-2 infections, where primary infections in unvaccinated persons are most infectious, followed by BNT162b2 breakthrough infections, mRNA-1273 breakthrough infections, and finally reinfections in unvaccinated persons. Strikingly, this hierarchy is the mirror image of the hierarchy observed in the efficacy against acquisition of infection. In our earlier studies on these national cohorts in Qatar, we found that those vaccinated with BNT162b2 had (relatively) the lowest protection against acquisition of infection (at 75% against the B.1.351 (Beta) variant4,11 that dominated incidence since the onset of vaccination19,20), while protection against acquisition of infection was considerably higher among those vaccinated with mRNA-12735 and those with a prior infection13–15,25. This may indicate that both VES and VEI are essentially inter-related manifestations of the strength of the vaccine-induced (or natural-infection-induced) immune response. When the immune response is strong against acquisition of infection, it also appears strong at reducing viral replication upon acquisition of the virus, leading to lower viral load and faster infection clearance. Thus, less secondary transmission occurs in breakthrough infections.

This study has limitations. The number of documented mRNA-1273 breakthrough infections was small, thereby limiting the statistical precision of the comparisons involving these infections, leading to estimates with wider 95% confidence intervals, and perhaps making them more prone to bias. The study was implemented on documented infections, but other infections may have occurred and gone undocumented. It is possible that breakthrough infections in those vaccinated or who had a prior infection are less likely to be documented, perhaps because of minimal/mild or no symptoms. However, with the high rate of PCR testing in Qatar, the majority of infections are identified not because of testing symptomatic cases, but because of testing for other reasons, such as random testing campaigns, contact tracing, individual requests, routine healthcare testing, pre-travel, and at ports of entry. The results of our study were also consistent when we included only the randomly diagnosed infections.

Imperfect assay sensitivity and specificity of RT-qPCR testing may have affected infection ascertainment, but RT-qPCR testing was performed using a validated commercial platform that has been used globally and has essentially 100% sensitivity and specificity26 (Methods). While it is established that SARS-CoV-2 viral load strongly correlates with culturable virus10 and infectiousness, the exact mathematical relationship linking viral load to infectiousness is not known. Therefore, we generated estimates for the relative infectiousness assuming a linear dependence on viral load, and alternatively assuming a non-linear (power-law) dependence on viral load, similar to that rigorously delineated for HIV infection22–24. Estimates for the relative infectiousness presented in Tables 4 and 5 are thus approximate and qualitative in nature, and should not be seen as precise quantitative measures.

View this table:
Table 4.

Relative infectiousness of all RT-qPCR confirmed infections, only the randomly diagnosed (asymptomatic) infections, and only the symptomatic infections across the six pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections. These estimates assume that SARS-CoV-2 infectiousness is linearly proportional to viral load. Estimates in the sensitivity analysis assuming that infectiousness is (non-linearly) proportional to some power of viral load, similar to that for HIV22–24, are found in Table 5.

View this table:
Table 5.

Sensitivity analysis for estimates of relative infectiousness. Relative infectiousness of all RT-qPCR confirmed infections, only the randomly diagnosed (asymptomatic) infections, and only the symptomatic infections across the six pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections. The sensitivity analysis estimates assume that SARS-CoV-2 infectiousness is (non-linearly) proportional to some power of viral load (vlα), just as for HIV, where the exponent α has been estimated at around 0.422–24. Estimates assuming that SARS-CoV-2 infectiousness is linearly proportional to viral load (that is α =1) are found in Table 4.

Unlike blinded, randomized clinical trials, the investigated observational cohorts were neither blinded nor randomized. Our cohorts predominantly included working-age adults; therefore, results may not necessarily be generalizable to other population groups, such as children or the elderly. Matching was done for sex, age, reason for the RT-qPCR testing, and calendar week of the RT-qPCR test, but could not be done for other factors, such as comorbidities, as these were not available to study investigators. But inclusion of additional factors in the matching would have considerably reduced the sample sizes—breakthrough infections in those vaccinated or who had a prior infection are relatively uncommon. It is noteworthy that matching by age and sex may have served as a proxy for matching by co-morbidity, as co-morbidities are associated with older age and may differ between women and men.

In conclusion, prior immunity, whether due to vaccination or prior infection, is associated with lower SARS-CoV-2 viral load upon infection. While breakthrough infections have been observed globally, they appear less infectious than primary infections; thus, they constitute a lesser public health concern. The public health benefits of vaccination are underestimated, as both the BNT162b2 and mRNA-1273 vaccines seem not only to protect against acquisition of infection, but also against transmission of infection. These findings justify optimism and stress the urgency to scale up vaccination globally in order to robustly control infection transmission and the extent of the pandemic.

Data Availability

The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.

Author contributions

LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.

Competing interests

Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests.

Methods

Data sources and study design

Analyses were conducted using the centralized, integrated, and standardized national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) databases compiled at Hamad Medical Corporation (HMC), the main public healthcare provider and the nationally designated provider for all Coronavirus Disease 2019 (COVID-19) health care needs. Through a nationwide digital health information platform, these databases are complete, and have captured all SARS-CoV-2-related data as well as related demographic details with no missing information since the start of the epidemic, including all records of polymerase chain reaction (PCR) testing, antibody testing, COVID-19 hospitalizations, vaccinations, infection severity classification per World Health Organization (WHO) guidelines27 (performed by trained medical personnel through individual chart reviews), and COVID-19 deaths, also assessed per WHO guidelines28.

Every real time reverse transcription-PCR (RT-qPCR) test conducted in Qatar, regardless of location (outpatient clinic, drive-thru, or hospital, etc.), is classified on the basis of symptoms and the reason for testing (clinical symptoms, contact tracing, random testing campaigns (surveys), individual requests, routine healthcare testing, pre-travel, and port of entry). Qatar has unique demographics by sex and nationality, since expatriates from over 150 countries comprise 89% of the population17,29.

The BNT162b2 and mRNA-1273 vaccines have been the vaccines of choice in the national immunization campaign in Qatar4,5,11,12. Nearly all individuals in the cohorts of this study were vaccinated (free of charge) in Qatar, rather than elsewhere. In rare situations where an individual received vaccination outside Qatar, that individual’s vaccination details were still recorded in the health system at the port of entry upon return to Qatar, given the national requirements and to benefit from privileges associated with vaccination, such as quarantine exemption12.

Leveraging the national databases, effects of vaccination and of prior infection on SARS-CoV-2 infectiousness were investigated by comparing the RT-qPCR cycle threshold (Ct) values in matched cohorts of primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2 breakthrough infections, and mRNA-1273 breakthrough infections. These types of infection are defined in the main text.

In total, six types of pairwise comparisons were conducted on the cohorts of this study, after matching in a 1:1 ratio by sex, 10-year age group, reason for RT-qPCR testing, and calendar week of the RT-qPCR test, to control for differences in biology by sex and age, as well as exposure risk17,18 and variant exposure4,19,20. It is noteworthy that the first SARS-CoV-2 epidemic wave in Qatar occurred before introduction of any variant of concern and peaked in late May, 202017,18. The second wave was triggered by introduction and expansion of the B.1.1.7 (Alpha30) variant and peaked in early March, 20214,5,19,20. The third wave was dominated by the B.1.351 (Beta30) variant, and peaked in the first week of April, 20214,5,19,20. The B.1.617.2 (Delta30) variant has been introduced only recently in Qatar, and as of July 11, 2021, it remains at low incidence19,20. There is no evidence that any other variant of concern is or has been responsible for appreciable community transmission in Qatar19,20.

Comparisons across the cohorts of infection were implemented for all RT-qPCR-confirmed infections, for only the symptomatic infections defined as RT-qPCR-positive tests conducted because of clinical suspicion due to symptoms compatible with a respiratory tract infection, and for only the randomly diagnosed (asymptomatic) infections defined as RT-qPCR-positive tests conducted with no prior reason to suspect infection and no reported symptoms compatible with a respiratory tract infection. The latter was strictly defined as an RT-qPCR-positive test conducted as part of a survey (random testing campaigns), for routine health care testing, as a pre-travel requirement, or at a port of entry upon arrival in the country4,5,12,17.

All records of RT-qPCR testing in Qatar were examined in this study, but only samples of matched cohorts were included in the analysis. Individuals with a record of a SARS-CoV-2 antibody-positive test before the first RT-qPCR-positive test were excluded from analysis of those with primary infections. Individuals with a record of vaccination before the reinfection diagnosis were excluded from the analysis of those with reinfection. Only breakthrough infections in fully vaccinated individuals were included in the analysis. Being fully vaccinated was defined as completion of ≥14 days after the second dose. Only individuals who had their first and second doses with the same vaccine were included in the analysis.

Further background on Qatar’s epidemic, such as on reinfections13,14, national seroprevalence surveys17,31–33, RT-qPCR surveys17, and other epidemiological studies can be found in previous publications on this epidemic4,5,11,17,18,34–40.

Reporting of the study followed the STROBE guidelines (Supplementary Table 3).

Laboratory methods

Nasopharyngeal and/or oropharyngeal swabs (Huachenyang Technology, China) were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on a QIAsymphony platform (QIAGEN, USA) and tested with real-time reverse-transcription PCR (RT-qPCR) using TaqPath™ COVID-19 Combo Kits (100% sensitivity and specificity26; Thermo Fisher Scientific, USA) on an ABI 7500 FAST (ThermoFisher, USA); extracted using a custom protocol41 on a Hamilton Microlab STAR (Hamilton, USA) and tested using AccuPower SARS-CoV-2 Real-Time RT-PCR Kits (100% sensitivity and specificity42; Bioneer, Korea) on an ABI 7500 FAST; or loaded directly into a Roche cobas® 6800 system and assayed with a cobas® SARS-CoV-2 Test (95% sensitivity, 100% specificity43; Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab regions. The second targets the viral RdRp and E-gene regions, and the third targets the ORF1ab and E-gene regions.

All tests were conducted at the HMC Central Laboratory or Sidra Medicine Laboratory, following standardized protocols.

Only the RT-qPCR-confirmed infections diagnosed using the TaqPath COVID-19 Combo Kits platform (Thermo Fisher Scientific, USA26) were included in the analysis, for standardization of Ct values. This platform processes >85% of all RT-qPCR tests in Qatar and reports individual Ct values for each of the N, ORF1ab, and S genes4,5,26. The average of these three Ct values was included in the analysis. The correlation between each pair of these Ct values across all RT-qPCR-positive tests was very strong with a Pearson correlation coefficient ≥0.976. In the case of a gene “target failure”, and specifically an S-gene “target failure” that was the defining characteristic of the B.1.1.7 cases44–46, the average determined using only the two Ct values of the N and ORF1ab genes.

Statistical analysis

Socio-demographic characteristics of study samples were described using frequency distributions and measures of central tendency. Differences in proportions across categorical variables between study groups were evaluated using Chi-square tests. The distributions of the RT-qPCR Ct values were illustrated using scatter plots and boxplots, and summarized using measures of central tendency and dispersion. Mean differences in the RT-qPCR Ct values between study groups and associated 95% confidence intervals (CIs) were calculated using independent t-tests. Two-sided p-value of <0.05 indicated a significant association. Statistical analyses were conducted in STATA/SE version 17.047.

RT-qPCR Ct value, viral load, and SARS-CoV-2 infectiousness

SARS-CoV-2 viral load (vl) can be approximately estimated from the RT-qPCR Ct value (n) using the mathematical formula21,26: Embedded Image where c0 is a constant that depends on each RT-qPCR platform and is experimentally derived factoring specimen buffers and extraction method among other factors.

Accordingly, in a pairwise comparison of RT-qPCR-confirmed infections in two cohorts, the ratio of the two viral loads is independent of the constant c0 and is given by Embedded Image where Δn is the difference in the RT-qPCR Ct values between these two cohorts.

SARS-CoV-2 viral load correlates strongly with cultivable virus10, and thus infectiousness, just as viral load for other viruses, such as HIV, is a measure of its infectiousness22–24. Therefore, the ratio of two viral loads in two cohorts can be considered to provide a measure of the relative infectiousness of these two cohorts. This implicitly assumes that SARS-CoV-2 infectiousness is linearly proportional to vl, the simplest default assumption for lack of data. This assumption was used in the baseline analysis for the relative infectiousness.

However, infectiousness could be related to viral load through a non-linear mathematical function. For HIV infection for instance, which has perhaps the best characterized relationship between viral load and infectiousness in the literature22–24, infectiousness is (non-linearly) proportional to vlα where the exponent α has been estimated at 0.3-0.522–24—that is infectiousness is approximately proportional to the square rate of viral load rather than the viral load itself. In a sensitivity analysis, we estimated SARS-CoV-2 relative infectiousness assuming that infectiousness is proportional to vlα with an α = 0.4, similar to that for HIV22–24, to provide an alternative estimate assuming a power-law mathematical function linking viral load to infectiousness.

Ethical approvals

The study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with waiver of informed consent.

Data availability

The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.

Supplementary Material

View this table:
Supplementary Table 1.

Demographic characteristics of the study populations in the three pairwise comparisons between primary infections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections.

View this table:
Supplementary Table 2.

Demographic characteristics of the study populations in three pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections.

Supplementary Figure 1.
Supplementary Figure 1.

RT-qPCR Ct values in all confirmed infections, regardless of the reason for the RT-qPCR testing. Distribution of these Ct values in the six pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections. Boxplots center lines indicate the median Ct values, box limits indicate the 25% and 75% quartiles, and whiskers indicate maximum and minimum observations within 1.5 of interquartile range.

Supplementary Figure 2.
Supplementary Figure 2.

RT-qPCR Ct values in the symptomatic SARS-CoV-2 infections. Distribution of these Ct values in the six pairwise comparisons between primary infections in unvaccinated individuals, reinfections in unvaccinated individuals, BNT162b2-vaccine breakthrough infections, and mRNA-1273-vaccine breakthrough infections. A symptomatic infection was defined as an RT-qPCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. Boxplots center lines indicate the median Ct values, box limits indicate the 25% and 75% quartiles, and whiskers indicate maximum and minimum observations within 1.5 of interquartile range.

View this table:
Supplementary Table 3. STROBE checklist.

Acknowledgements

We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, and the Qatar Biobank for their diligent efforts and contributions to make this study possible. The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health and Hamad Medical Corporation. The authors are also grateful for the Qatar Genome Programme for supporting the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors.

References

  1. 1.↵
    Polack, F.P., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med (2020).
  2. 2.↵
    Baden, L.R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403–416 (2021).
    OpenUrlCrossRefPubMed
  3. 3.↵
    Forni, G., Mantovani, A. & Covid-19 Commission of Accademia Nazionale dei Lincei, R. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28, 626–639 (2021).
    OpenUrlCrossRefPubMed
  4. 4.↵
    Abu-Raddad, L.J., Chemaitelly, H., Butt, A.A. & National Study Group for Covid-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med (2021).
  5. 5.↵
    Chemaitelly, H., et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med (2021).
  6. 6.↵
    CDC Covid-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 70, 792–793 (2021).
    OpenUrlCrossRef
  7. 7.↵
    Makhoul, M., et al. Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. Vaccines (Basel) 8 (2020).
  8. 8.↵
    Letizia, A.G., et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med 9, 712–720 (2021).
    OpenUrl
  9. 9.↵
    Thompson, M.G., et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med (2021).
  10. 10.↵
    Singanayagam, A., et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill 25 (2020).
  11. 11.↵
    Abu-Raddad, L.J., et al. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med (2021).
  12. 12.↵
    Bertollini, R., et al. Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. JAMA (2021).
  13. 13.↵
    Abu-Raddad, L.J., et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine 35, 100861 (2021).
    OpenUrl
  14. 14.↵
    Abu-Raddad, L.J., et al. Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting. Clin Infect Dis (2020).
  15. 15.↵
    Chemaitelly, H., et al. Reinfections with the SARS-CoV-2 B.1.351 variant and efficacy of natural immunity against reinfection under review at New England Journal of Medicine (2021).
  16. 16.↵
    Hansen, C.H., Michlmayr, D., Gubbels, S.M., Molbak, K. & Ethelberg, S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet (2021).
  17. 17.↵
    Abu-Raddad, L.J., et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Scientific Reports 11, 6233 (2021).
    OpenUrl
  18. 18.↵
    Ayoub, H.H., et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. J Glob Health 11, 05005 (2021).
    OpenUrl
  19. 19.↵
    National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. https://www.gisaid.org/phylodynamics/global/nextstrain/. (2021).
  20. 20.↵
    Benslimane, F.M., et al. One year of SARS-CoV-2: Genomic characterization of COVID-19 outbreak in Qatar. medRxiv, 2021.2005.2019.21257433 (2021).
  21. 21.↵
    Thermo Fisher Scientific. Real-Time PCR: Understanding Ct. Available from: https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/PG1503-PJ9169-CO019879-Re-brand-Real-Time-PCR-Understanding-Ct-Value-Americas-FHR.pdf. Accessed on July 16, 2021. xVol. 2021 (2016).
  22. 22.↵
    Hughes, J.P., et al. Determinants of per-coital-act HIV-1 infectivity among African HIV- 1-serodiscordant couples. The Journal of Infectious Diseases 205, 358–365 (2012).
    OpenUrlCrossRefPubMed
  23. 23.
    Quinn, T.C., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. The New England Journal of Medicine 342, 921–929 (2000).
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    Nagelkerke, N., Abu-Raddad, L.J., Awad, S.F., Black, V. & Williams, B. A signature for biological heterogeneity in susceptibility to HIV infection? Infect Dis Model 3, 139–144 (2018).
    OpenUrl
  25. 25.↵
    Abu-Raddad, L.J., et al. Epidemiologic characterization of introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and its reinfections in a national population. Under review (2021).
  26. 26.↵
    Thermo Fisher Scientific. TaqPath™ COVID-19 CE-IVD RT-PCR Kit instructions for use. Available from: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0019215_TaqPathCOVID-19_CE-IVD_RT-PCR%20Kit_IFU.pdf. Accessed on December 02, 2020. (2020).
  27. 27.↵
    World Health Organization. COVID-19 clinical management: living guidance. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Accessed on: May 15, 2021. (2021).
  28. 28.↵
    World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1. Document Number: WHO/HQ/DDI/DNA/CAT. Accessed on May 15, 2021. (2020).
  29. 29.↵
    Planning and Statistics Authority-State of Qatar. Qatar Monthly Statistics. Available from: https://www.psa.gov.qa/en/pages/default.aspx. Accessed on: May 26, 2020. (2020).
  30. 30.↵
    World Health Organization. Tracking SARS-CoV-2 variants. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed on: June 5, 2021. (2021).
  31. 31.↵
    Coyle, P.V., et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. iScience, 102646 (2021).
  32. 32.
    Jeremijenko, A., et al. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerg Infect Dis 27, 1343–1352 (2021).
    OpenUrl
  33. 33.↵
    Al-Thani, M.H., et al. SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. Open Forum Infectious Diseases (2021).
  34. 34.↵
    Al Kuwari, H.M., et al. Epidemiological investigation of the first 5685 cases of SARS- CoV-2 infection in Qatar, 28 February-18 April 2020. BMJ Open 10, e040428 (2020).
    OpenUrlCrossRefPubMed
  35. 35.
    Ayoub, H.H., et al. Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innovations, bmjinnov-2021-000677 (2021).
  36. 36.
    Butt, A.A., et al. Hospital admission rates, length of stay, and in-hospital mortality for common acute care conditions in COVID-19 vs. pre-COVID-19 era. Public Health 189, 6–11 (2020).
    OpenUrlCrossRefPubMed
  37. 37.
    Saththasivam, J., et al. COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar. Sci Total Environ 774, 145608 (2021).
    OpenUrl
  38. 38.
    Seedat, S., et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates. medRxiv 2020.11.29.20240416 (2020).
  39. 39.
    Abu-Raddad, L.J., et al. Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. Infect Genet Evol 88, 104684 (2020).
    OpenUrl
  40. 40.↵
    Nasrallah, G.K., et al. Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci Rep 11, 11837 (2021).
    OpenUrl
  41. 41.↵
    Kalikiri, M.K.R., et al. High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads. medRxiv, 2020.2004.2008.20055731 (2020).
  42. 42.↵
    Kubina, R. & Dziedzic, A. Molecular and Serological Tests for COVID-19 a Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics. Diagnostics (Basel) 10 (2020).
  43. 43.↵
    US Food and Drug Administration. Cobas® SARS-CoV-2: Qualitative assay for use on the cobas® 6800/8800 Systems. Avilable from: https://www.fda.gov/media/136049/download. Accessed on: December 02, 2020. (2020).
  44. 44.↵
    European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf. Accessed on: February 10, 2021. (Stockholm; 2020, 2020).
  45. 45.
    Galloway, S.E., et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep 70, 95–99 (2021).
    OpenUrlCrossRefPubMed
  46. 46.↵
    Challen, R., et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 372, 579 (2021).
    OpenUrlCrossRef
  47. 47.↵
    StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC. (2021).
Back to top
Posted July 30, 2021.
Download PDF
Data/Code
Email
Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections
Laith J. Abu-Raddad, Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, Peter Coyle, Mohammad R. Hasan, Hadi M. Yassine, Fatiha M. Benslimane, Hebah A. Al Khatib, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al Kuwari, Adeel A. Butt, Hamad Eid Al Romaihi, Abdullatif Al Khal, Mohamed H. Al-Thani, Roberto Bertollini
medRxiv 2021.07.28.21261086; doi: https://doi.org/10.1101/2021.07.28.21261086
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area